Beijing Sun-Novo Pharmaceutical Research Co Ltd. Stock Analysis 688621.SS

Beijing Sun-Novo Pharmaceutical Research Co., Ltd. engages in the research and development of pharmaceutical products. The company is headquartered in Beijing, Beijing and currently employs 1,335 full-time employees. The company went IPO on 2021-06-21. The firm's main businesses cover comprehensive research and development services in drug development, generic drug development and consistency assessment. The firm's services mainly comprise drug discovery, pharmacology and pharmacodynamics, pharmacy research, clinical research and bioanalysis. The firm's pharmaceutical research services cover the fields of drug discovery, small nucleic acid drug development, peptide drug research and development, and sustained-release formulation development. The firm's clinical trials and bioanalyses services include phase I-IV clinical trials, bioequivalence (BE) trials and others. The firm mainly conducts its businesses in the domestic market.